


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/970,558
		Filing Date	October 4, 2001
		First Named Inventor	David R. Carver
		Group Art Unit	1614
		Examiner Name	Dwayne C. Jones
		Attorney Docket Number	NPB-100D5

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	R1	ROGER W. MILLER et al., Antileukemic Alkaloids from Taxus wallichiana Zucc., J. Org. Chem, 1981, 46:1469-1474.
	R2	National Cancer Institute, Division of Cancer Treatment, Bethesda, Maryland, Clinical Brochure, Taxol IND 22850. NSC 125973, July 1991, pages 1-36.
	R3	ABRAHAM E. MATHEW et al., Synthesis and Evaluation of Some Water-Soluble Prodrugs and Derivatives of Taxol with Antitumor Activity, J. Med. Chem., 1992, 35:145-151.
	R4	J.R. KAGEL et al., Taxol Stability in Aqueous Solutions or in Organic/Aqueous Cosolvents, 8 th AAPS National Meeting, Orlando, FL, November 14-18, 1993.
	R5	National Cancer Institute, Division of Cancer Treatment, Bethesda, Maryland, Clinical Brochure, Taxol NSC 125973, September 1983, pages 1-54.
	R6	Professor Blechert's Israeli Declaration filed in the Israel Opposition to a related application, and also made of record in the European Opposition.
	R7	SUSAN G. ARBUCK et al., A Reassessment of Cardiac Toxicity Associated with Taxol, Journal of the National Cancer Institute Monographs, 1993, 15:117-130.
	R8	K. REBER, Inhibition of Haemolysis by 'Cremophor' in Conserved Blood, Nature, October 9, 1965, 208(5006):195.
	R9	Taxol Brochure, MeadJohnson Oncology Products, A Bristol-Myers Squibb Company, July 2000, 6 pages.
	R10	National Cancer Institute, Division of Cancer Treatment, Bethesda, Maryland, Annual Report to the Food and Drug Administration, Taxol IND 22850 NSC 125573, February 1989, pages 1-25.
	R11	English language translation of informal signed statement from Professor Blechert attesting to various pH determinations which he purported he had carried out, June 2002.
	R12	Decision issued by the European Patent Office revoking European Patent No. 0674510.
	R13	Consolidated Document List cited all reference documents relied on during prosecution of the Appeal process of European Patent No. 0674510.

Examiner Signature		Date Considered	8/10/03
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/970,558
Filing Date	October 4, 2001
First Named Inventor	David R. Carver
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	NPB-100D5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1					
	U2					
	U3					
	U4					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1							
	F2							
	F3							
	F4							

Examiner
Signature

David R. Carver

Date
Considered

8/10/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/970,558
Filing Date	October 4, 2001
First Named Inventor	David R. Carver
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	NPB-100D5

OTHER—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	NaPro Biotherapeutics, Inc. and Abbott Laboratories v. Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc. and UDL Laboratories, Inc., Civil Action No. 01-CV-1048 (W.D. PA), Stipulation and Protective Order.	
	R2	NaPro Biotherapeutics, et al. v. Mylan Laboratories, et al., Case No. 01-CV-1048 (W.D. PA), Patent Infringement, litigation, court docket.	
	R3	NaPro Biotherapeutics, Inc., et al. v. Bristol-Myers Squibb Co., Case No. 00-CV-1818 (D. CO), Patent Infringement, litigation, court docket.	
	R4	NaPro Biotherapeutics, Inc. and Abbott Laboratories v. Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc. and UDL Laboratories, Inc., Civil Action No. 01-CV-1048 (W.D. PA), Amended Answer and Counterclaims of Defendants to Second Amended Complaint.	
	R5	NaPro Biotherapeutics, Inc. and Abbott Laboratories v. Bristol-Myers Squibb Co., Civil Action No. 00-B-1818 (D. CO), Defendant's Responses and Objections to Plaintiffs' First Set of Interrogatories.	
	R6	NaPro Biotherapeutics, Inc. and Abbott Laboratories v. Bristol-Myers Squibb Co., Civil Action No. 00-B-1818 (D. CO), Defendant's Answer to First Amended Complaint.	
	R7	Information Disclosure Statement dated November 26, 1996 filed in parent application USSN 08/594,478, now U.S. Patent No. 5,733,888.	
	R8		

Examiner
Signature

Date

Considered

8/10/13

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.